IMAGE: Steven A. Rosenberg, M.D., Ph.D., will be the recipient of the 2019 Szent-Györgyi Prize. view more
Credit: National Institutes of Health
The 2019 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to Steven A. Rosenberg, M.D., Ph.D., of the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), one of the National Institutes of Health. The prize, awarded annually by the National Foundation for Cancer Research (NFCR), recognizes Dr. Rosenberg’s pioneering role in the development of adoptive immunotherapy to treat cancer.
Dr. Rosenberg, chief of CCR’s Surgery Branch, developed the first effective immunotherapies and gene therapies for selected patients with advanced cancer and was the first to successfully insert foreign genes–in this case, genetically modified T cells–into humans. His immunotherapy clinical trials have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas, lymphomas, and other cancers.
“Dr. Rosenberg’s groundbreaking work has changed cancer research and what we know about treatment, but his findings have also immeasurably changed patients’ lives,” said NCI Director Ned Sharpless, M.D. “We are proud to see him awarded the Szent-Györgyi Prize, which recognizes work that has lasting impact while also honoring the importance of basic research in understanding cancer.”
Dr. Rosenberg’s clinical trials
Article originally posted at